CN110511285B - 一种重组融合多肽及其应用 - Google Patents
一种重组融合多肽及其应用 Download PDFInfo
- Publication number
- CN110511285B CN110511285B CN201910795102.XA CN201910795102A CN110511285B CN 110511285 B CN110511285 B CN 110511285B CN 201910795102 A CN201910795102 A CN 201910795102A CN 110511285 B CN110511285 B CN 110511285B
- Authority
- CN
- China
- Prior art keywords
- fibrosis
- recombinant fusion
- fusion polypeptide
- polypeptide
- gly gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 118
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 118
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 118
- 230000004927 fusion Effects 0.000 title claims abstract description 94
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 26
- 201000002793 renal fibrosis Diseases 0.000 claims abstract description 19
- 206010028594 Myocardial fibrosis Diseases 0.000 claims abstract description 18
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 16
- 206010050207 Skin fibrosis Diseases 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 34
- 230000004761 fibrosis Effects 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 21
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 208000026062 Tissue disease Diseases 0.000 claims description 5
- 210000004879 pulmonary tissue Anatomy 0.000 claims description 4
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims description 2
- 201000005019 Chlamydia pneumonia Diseases 0.000 claims description 2
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 claims description 2
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 claims description 2
- 206010035737 Pneumonia viral Diseases 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 claims description 2
- 208000009421 viral pneumonia Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 4
- 230000003510 anti-fibrotic effect Effects 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000007922 nasal spray Substances 0.000 claims 2
- 229940097496 nasal spray Drugs 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000003902 lesion Effects 0.000 abstract description 4
- 230000003176 fibrotic effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 29
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 29
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 29
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 29
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- 210000002950 fibroblast Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 16
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 210000002744 extracellular matrix Anatomy 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 14
- 238000010171 animal model Methods 0.000 description 14
- 229920001436 collagen Polymers 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 230000004913 activation Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 10
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 10
- 102000006495 integrins Human genes 0.000 description 10
- 108010044426 integrins Proteins 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 241000269331 Ambystoma Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 8
- 229960002591 hydroxyproline Drugs 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 8
- 108010006654 Bleomycin Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229960001561 bleomycin Drugs 0.000 description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000008021 deposition Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000003146 transient transfection Methods 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010023421 Kidney fibrosis Diseases 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 210000000651 myofibroblast Anatomy 0.000 description 5
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 4
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 241000205573 Jeffersonia Species 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 229940039009 isoproterenol Drugs 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000000626 ureter Anatomy 0.000 description 4
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 3
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 3
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- MYKLINMAGAIRPJ-CIUDSAMLSA-N Met-Gln-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O MYKLINMAGAIRPJ-CIUDSAMLSA-N 0.000 description 3
- 206010054949 Metaplasia Diseases 0.000 description 3
- OLHDPZMYUSBGDE-GUBZILKMSA-N Pro-Arg-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O OLHDPZMYUSBGDE-GUBZILKMSA-N 0.000 description 3
- CJNCVBHTDXKTMJ-CYDGBPFRSA-N Ser-Asp-Lys-Pro Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O CJNCVBHTDXKTMJ-CYDGBPFRSA-N 0.000 description 3
- FOAJSVIXYCLTSC-PJODQICGSA-N Trp-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N FOAJSVIXYCLTSC-PJODQICGSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 210000004024 hepatic stellate cell Anatomy 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000015689 metaplastic ossification Effects 0.000 description 3
- 108010085203 methionylmethionine Proteins 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 229960004378 nintedanib Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 108010003885 valyl-prolyl-glycyl-glycine Proteins 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OERMIMJQPQUIPK-FXQIFTODSA-N Asp-Arg-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O OERMIMJQPQUIPK-FXQIFTODSA-N 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 229940124761 MMP inhibitor Drugs 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- SCQBNMKLZVCXNX-ZFWWWQNUSA-N Trp-Arg-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N SCQBNMKLZVCXNX-ZFWWWQNUSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 108010078274 isoleucylvaline Proteins 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- HZKLCOYAVAAQRD-VGMNWLOBSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxyethyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N HZKLCOYAVAAQRD-VGMNWLOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- VEAPAYQQLSEKEM-GUBZILKMSA-N Ala-Met-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(O)=O VEAPAYQQLSEKEM-GUBZILKMSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- IZJLAQMWJHCHTN-BPUTZDHNSA-N Cys-Trp-Arg Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O IZJLAQMWJHCHTN-BPUTZDHNSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- ZPDVKYLJTOFQJV-WDSKDSINSA-N Gln-Asn-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ZPDVKYLJTOFQJV-WDSKDSINSA-N 0.000 description 1
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GLLAUPMJCGKPFY-BLMTYFJBSA-N Ile-Ile-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 GLLAUPMJCGKPFY-BLMTYFJBSA-N 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种重组融合多肽及其制备方法和其应用。一种重组融合多肽,所述的重组融合多肽由以下通式表述:X‑linker1‑Y;Y‑linker1‑X;X‑linker2‑Y;Y‑linker2‑X;其中X为:PRCWRGEGGGGIVRRADRAAVPGGGGRGD;Y为:Acetyl‑SDKPGGGGTSLDASIIWAMMQNGGGGLSKL。本发明的重组融合多肽可以治疗各种纤维化疾病及病状,治疗用途包括抗肺纤维化、肝纤维化、皮肤纤维化、肾纤维化和心肌纤维化以及肺部组织病变。
Description
技术领域
本发明属于生物药物领域,更具体涉及一种重组融合多肽及其应用。
背景技术
组织纤维化(fibrosis)是一种器官组织实质细胞减少,纤维结缔组织增多性疾病,持续发展可致器官结构破坏和功能减退,最终衰竭,严重威胁患者健康。在世界范围内,组织器官纤维化是许多疾病致残、致死的主要原因。
在组织纤维化的发生过程中,成纤维母细胞和肌成纤维细胞是组织纤维化的关键效应细胞,这些效应细胞可以大量释放构成ECM的胶原成分,诸如Ⅰ型和Ⅲ型胶原。多种细胞因子也参与纤维化的进程,其中最关键的是转化生长因子-β(TGF-β)。TGF-β是调节细胞增殖、分化的多功能细胞生长因子,可以通过直接刺激原位成纤维细胞的活化或通过内皮间质(endothelial-mesenchymal transition,EnMT)、上皮间质化(epithelial-mesenchymaltransition,EMT)过程来刺激肌成纤维细胞的大量增殖和ECM的过度合成。TGF-β由于损伤持续被活化时,会交叉激活MAPK、EGF、Wnt/β-catenin信号,导致纤维化的发展。除了TGF-β外,对血小板衍生因子(PDGF)、碱性成纤维细胞生长因子(bFGF)、结缔组织生长因子(CTGF)、胰岛素样生长因子(IGF)、血管新生相关细胞因子、整合素、金属基质蛋白酶(MMP)及其抑制剂(TIMP)、肾素血管紧张素相关蛋白、利钠肽等的调节也将影响纤维化的发生。
本发明设计的重组融合多肽,具有多个靶点,具有金属基质蛋白酶抑制剂和抑制血管生成和抑制整合素等的功效,MMP抑制剂从调节ECM和肺部损伤的关键细胞因子MMP/TIMP着手,血管生成抑制剂可以抑制细胞因子的释放如TGF-β1、VEGF等,整合素可以与TGF-β结合,促进TGF-β的活化,释放细胞因子TGF-β1,抑制整合素可以抑制TGF-β1的释放,可以抑制成纤维细胞的增殖和活化,其可以从病理学上的主要发病机制作用于肺纤维化的治疗。多肽X和Y是针对不同靶点的多肽,其通过Linker链接并经重组表达后,具有多个靶点活性,起到了更好的治疗作用。并且可减少药物给药剂量和频率,改善病人对治疗的依从性和耐受性。
1.肺纤维化
肺纤维化(Pulmonary fibrosis,PF)是由多种因素引起的严重肺间质疾病,以肺成纤维细胞灶形成和ECM过度积聚为特征,鉴于肺组织对损伤后产生的病理反应及疾病特征相似,因此在临床上将肺纤维化统称为间质性肺病(Interstitial lung Disease,ILD)。ILD是以弥漫性肺实质、肺泡炎症和间质纤维化为病理基本病变。部分病因明确,而部分病因不明,若病因不明确则称其为特发性肺纤维化(Idiopathic pulmonary fibrosis,IPF)。特发性肺纤维化在肺纤维化中发病率最高,多发于老年男性,且中位生存率为3年,为目前研究的重点。
肺纤维化是肺组织过度修复的过程,Wilson指出,当“损伤-炎症-修复”链中任一或多个环节出现问题都会导致纤维化的发生。目前,可将肺纤维化的发生归结于以下三个阶段:(1)损伤阶段:肺泡上皮细胞受到气体、粉尘、感染(细菌或病毒)、药物、放射性损伤等等因素的刺激而受损;(2)效应阶段:损伤会促使肺泡上皮细胞凋亡,产生氧化应激反应,损伤部位募集炎症细胞(巨噬细胞、T/B淋巴细胞、中性粒细胞等等)和大量分泌的转化生长因子-β(TGF-β)会刺激成纤维细胞的增殖和分化,促使肺成纤维细胞灶形成;(3)纤维化阶段:成纤维细胞灶的形成并促使细胞外基质(ECM)的过度分泌,致使肺组织实质细胞逐步被间质细胞取代,肺组织失去弹性,硬度增加,最终使肺组织失去生理功能,致使患者因纤维化造成的呼吸衰竭而死亡。
多种细胞参与了纤维化的发生,如肺上皮细胞、内皮细胞、肺炎症细胞(主要为巨噬细胞)和肺间质细胞(成纤维细胞、肌纤维母细胞),其中肺间质细胞为肺纤维化发生的关键效应细胞。同时,细胞分泌的细胞因子诸如转化生长因子-β(TGF-β)、血小板衍生因子(PDGF)、碱性成纤维细胞生长因子(bFGF)、结缔组织生长因子(CTGF)、胰岛素样生长因子(IGF)、血管内皮生长因子(VEGF)、整合素、金属基质蛋白酶(MMP)及其抑制剂(TIMP)等等也对肺纤维化的发生影响颇深。
细胞因子中最关键的是TGF-β,TGF-β是可以调节细胞增殖、分化的多功能细胞生长因子。可以通过直接刺激原位成纤维细胞的活化或通过内皮间质化(EnMT)、上皮间质化(EMT)过程来刺激肌成纤维细胞的大量增殖和ECM的过度积聚。当TGF-β由于损伤持续被活化时,会交叉激活MAPK、EGF、Wnt/β-catenin信号,导致纤维化的发展。PDGF、bFGF、VEGF作为生长因子均可促进肺成纤维细胞的增殖和分化,对肺纤维化的进展产生影响。MMP/TIMP为ECM的主要调节剂,两者的含量在ECM的平衡中起到关键作用。这些细胞因子都或多或少对肺成纤维细胞的增殖和活化及胶原的形成产生影响,因此合理调控细胞因子的表达将有助于肺纤维化的治疗。
本发明设计的重组融合多肽,具有多重靶点,具有金属基质蛋白酶抑制剂和抑制血管生成和抑制整合素等的功效,MMP抑制剂从调节ECM和肺部损伤的关键细胞因子MMP/TIMP着手,血管生成抑制剂可以抑制细胞因子的释放如TGF-β1、VGFE等,整合素可以与TGF-β结合,促进TGF-β的活化,释放细胞因子TGF-β1,抑制整合素可以抑制TGF-β1的释放,可以抑制成纤维细胞的增殖和活化,其可以从病理学上的主要发病机制作用于肺纤维化的治疗。
2.肝纤维化
肝纤维化(liver fibrosis)是多种原因引起的慢性肝损害所致的病理改变,表现为肝内细胞外间质成分过度异常地沉积,并影响肝脏的功能,是慢性肝病发展到肝硬化必经之阶段。能够引起几乎各种慢性肝病的因素均可引起肝纤维化,其病因大致可分为感染性、先天性代谢缺陷、化学毒物性、自身免疫性肝病等。肝脏内细胞外基质的过度沉积是肝纤维的特征性变。目前认为,肝星形细胞(HSCs)的激活是肝纤维化发生的中心环节,但肝纤维化的发生和发展机制十分复杂,目前研究主要围绕肝脏星状细胞的激活和转化为肌成纤维细胞和成纤维细胞,其可能途径是激活转化生长因子-β(TGF-β)信号转导通路、血管衍生生长因子(PDGF)受体介导的信号转导通路、TNF-α介导的信号转导通路及前列腺素内氧化还原酶(COX-2)、弥漫性细胞外基质(ECM)、血管新生及氧化应激介导的肝纤维化等。
肝纤维化是各种慢性肝炎发展为肝硬化必经的病理阶段,是肝脏自我损伤修复的表现。据卫生组织报道,我国具有乙型肝炎病毒感染人群2000万例,此类患者绝大多数存在肝纤维化的发生,因此治疗肝纤维化已经成为迫切需要解决的问题。
3.肾纤维化
肾纤维化(包括肾小球纤维化、肾间质纤维化、肾血管纤维化)是几乎所有肾脏疾病进展到终末期肾功能衰竭的共同通路,是各种慢性肾脏疾病主要的病理学表现之一,是各种肾小球、血管和小管间质本身疾病的最后结局。有研究表明无论何种病因的肾脏病,肾纤维化的发展均是进行性的,其中肾小球纤维化和肾间质纤维化在肾纤维化中起重要作用。
肾脏由于受到创伤、感染、炎症、血循环障碍,以及免疫反应等多种致病因素刺激,其固有细胞受损,发展到后期出现大量胶原沉积和积聚,造成肾实质逐渐硬化,形成瘢痕,直至肾脏完全丧失脏器功能。肾脏内固有细胞纤维化、硬化的过程也就是肾脏纤维化的过程。在肾纤维化发生过程中肾间质炎症细胞浸润、成纤维细胞激活、细胞外基质过分沉积等均与整合素异常表达有关。肾纤化的基本病理学原因是成纤维细胞的过度活化,抑制成纤维细胞的过度活化,可以有效抑制肾纤维化的发展。
目前大多数肾纤维化治疗药物存在毒性大、安全性低、药理作用单一等问题,本发明的重组融合多肽是多靶点设计,可以从多个途径抑制肾纤维化的发生。
4.皮肤纤维化
皮肤纤维化(skinfibrosis)为皮肤的过度瘢痕形成,且为病理性伤口愈合反应的结果。皮肤伤口愈合包括几个阶段:止血,炎症,增殖,和组织成熟。整个过程由一系列复杂的因子(如生长因子和细胞因子)诱导和调节。皮肤纤维化可由免疫、自身免疫性和炎症机制驱动。胶原合成和降解这两者之间的平衡在纤维化的病理过程中起着关键的作用。某些细胞因子促进伤口愈合和纤维化,诸如TGF-β和白介素-4(IL-4),而其他细胞因子抗纤维化,诸如干扰素-γ(IFN-γ)和肿瘤坏死因子-α(TNF-α)。正常皮肤的纤维母细胞处于静止状态,当皮肤损伤后,成纤维细胞开始活化大量增殖、表达α-平滑肌肌动蛋白(α-SMA)且合成大量结缔组织蛋白。
用于治疗皮肤纤维化的最常用的方法是采用免疫抑制的疗法。基本原理在于,自身免疫性病因造成疾病的炎症方面以及后续组织损伤和纤维化。所常用的药物包括甲胺喋呤、环磷酰胺和环孢菌素。尽管已观察到免疫抑制疗法的一些改进,但关于药物安全性的担忧以及确定的临床数据和可证实的功效的缺乏仍然存在。因此临床急需开发用于治疗皮肤纤维化、纤维化皮肤疾病和皮肤的病理性瘢痕形成的有效药物制剂。
5.心肌纤维化
心肌纤维化是以心脏间质成纤维细胞过度增殖、胶原过度沉积以及异常分布为特征的心脏间质重构。心肌纤维化在病理特点上主要表现为胶原沉积的增多,各种不同胶原的比例失调,尤其是I型、III型胶原的比例升高、排列紊乱,同时伴有心肌成纤维细胞的增生。细胞外基质的合成与降解受多种因素的影响,基质金属蛋白酶-9(MMP-9)及其组织抑制物-1(TIMP-1)的平衡是降解过程中主要调节因素。目前MMP-9/TIMP-1在心肌纤维中的作用日益受到重视。心肌纤维化与高血压病、慢性心力衰竭、扩张型心肌病等多种心血管疾病有密切的关系,并且心源性猝死的潜在的危险因素。目前对心肌纤维化的具体发病机制并不是十分的明确,主要认为与肾素--血管紧张素-醛固酮系统、各种细胞因子、氧化应激等存在密切的关系。这些因素通过相同或者不同的传导通路影响着心肌纤维化的发与发展。
目前还没有针对治疗心肌纤维化的上市药物,因此临床急需开发一种药物用于治疗心肌纤维化。
发明内容
要解决的问题
针对现有多肽化学合成成本高,杂质多,靶点单一等问题,本发明提供一种具有一种重组融合多肽,本发明的重组融合多肽采用293T细胞培养表达的方法,将两种不同活性靶点的多肽进行连接,代替了化学合成方法,降低成本,减少杂质,其连接增加了重组多肽的作用靶点和疗效,两种多肽的连接,使其具有两种多肽各自靶点,使重组融合多肽具有多个靶点活性功能,在肺纤维化、肝纤维化、肾纤维化、心肌纤维化、皮肤纤维化以及肺组织病变方面均具有很好的治疗效果。本发明的重组融合多肽可以靶向多个靶点,可以从多个途径抑制纤维化的发生。
技术方案
为了解决上述的问题,本发明采用的技术方案如下:
一种重组融合多肽,所述的重组融合多肽由以下通式表述:
X-linker1-Y;Y-linker1-X;X-linker2-Y;Y-linker2-X;
其中X为:PRCWRGEGGGGIVRRADRAAVPGGGGRGD;
Y为:Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL。
所述的重组融合多肽的linker1为:GGGGSGGGGSGGGGS;linker2为:AEAAAKEAAAKEAAAKEAAAKK。
具体来说一种重组融合多肽,具有抗纤维化的活性,其氨基酸序列为:
重组融合多肽I:
PRCWRGEGGGGIVRRADRAAVPGGGGRGD-linker1-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
重组融合多肽II:
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL-linker1-PRCWRGEGGGGIVRRADRAAVPGGGGRGD;
重组融合多肽III:
PRCWRGEGGGGIVRRADRAAVPGGGGRGD-linker2-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL
重组融合多肽IV:
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL-linker2-PRCWRGEGGGGIVRRADRAAVPGGGGRGD。
优选的序列如下:
PRCWRGEGGGGIVRRADRAAVPGGGGRGDGGGGSGGGGSGGGGSSDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKLGGGGSGGGGSGGGGSPRCWRGEGGGGIVRRADRAAVPGGGGRGD;
PRCWRGEGGGGIVRRADRAAVPGGGGRGDAEAAAKEAAAKEAAAKEAAAKKSDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKLAEAAAKEAAAKEAAAKEAAAKKPRCWRGEGGGGIVRRADRAAVPGGGGRGD;
本发明多肽还包括含有以上序列80%同源性的多肽序列。
上述的一种重组融合多肽在抗人肺纤维化、肝纤维化、肾纤维化、心肌纤维化、皮肤纤维化和抗肺部组织病变药物中的应用。
优选地,所述的肺部组织病变包括所述的抗肺组织病变包括细菌性肺炎、病毒性肺炎、支原体肺炎、真菌性肺炎、衣原体肺炎、原虫性肺炎。
本发明的重组融合多肽具有多重靶点,可以靶向血管新生、整合素、基质金属蛋白酶等,可以从多个方面抑制纤维化的进程,减少成纤维细胞的活化,减少细胞外基质的沉积,可以减缓上述纤维化的进程,同时还可以抑制多种肺部疾病的感染。
有益效果
相比于现有的技术,本发明的有益效果为:
(1)本发明的重组融合多肽分子由一种柔性或者刚性Linker连接,两端多肽可变化移动,从而有更好的延展性,多肽X和多肽Y具有不同的靶点,可以从多个方面抑制纤维化的进程;
(2)本发明的重组融合多肽通过柔性或者刚性的Linker将两条多肽重组连接,增加了多肽分子的分子量,延长了药物的半衰期,增强了稳定性,提高了药效;
(3)本发明的一种重组融合多肽可以用于治疗多种纤维化疾病,包括肺、肝、肾、心肌以及皮肤纤维化。
(4)本发明的重组融合多肽对肺纤维化模型中,可以显著降低肺组织中HYP和TGF-β1的表达含量,明显改善肺纤维化的状况,延长其生命周期;
(5)本发明的重组融合多肽对肝纤维化模型中,可以显著降低肝组织中HYP的表达含量,明显改善肝纤维化的状况;
(6)本发明的重组融合多肽在肾纤维化的模型中,可以显著降低肾组织中TGF-β1的表达含量,明显改善肾纤维化的状况;
(7)本发明的重组融合多肽在心肌纤维化的模型中,可以显著降低心脏组织中HYP的含量,明显改善心肌纤维化的状况;
(8)本发明重组融合多肽在皮肤纤维化的模型中,可以显著降低皮肤中HYP的表达含量,明显改善皮肤瘢痕增生的情况;
(9)本发明的重组融合多肽对肺部疾病的感染,也具有良好的抑制作用,抑制率达78%以上。
附图说明
图1是本发明的重组融合多肽I、II、III、IV可以降低肺纤维化模型中羟脯氨酸含量的图;
图2是本发明的重组融合多肽I、II、III、IV可以降低肺纤维化模型中TGF-β1含量的图;
图3是本发明的重组融合多肽I、II、III、IV可以降低肝纤维化模型中HYP含量的图;
图4是本发明的重组融合多肽I、II、III、IV可以降低肾纤维化模型中TGF-β1含量的图;
图5是本发明的重组融合多肽I、II、III、IV可以降低心肌纤维化模型中TGF-β1含量图;
图6是本发明的重组融合多肽I、II、III、IV可以降低皮肤纤维化模型中羟脯氨酸含量的图;
图7是本发明的重组融合多肽I、II、III、IV对肺部感染的抑制效果;
注释:融合多肽I、II、III、IV,即为融合多肽1、2、3、4,下同。
具体实施方式
实施例1、重组融合多肽I、II、III、IV的制备
重组融合多肽I:X-linker1-Y;氨基酸序列为:
PRCWRGEGGGGIVRRADRAAVPGGGGRGD-linker1-Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
重组融合多肽II:Y-linker1-X,氨基酸序列为:
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL-linker1-PRCWRGEGGGGIVRRADRAAVPGGGGRGD;
重组融合多肽III:X-linker2-Y;氨基酸序列为:
PRCWRGEGGGGIVRRADRAAVPGGGGRGD-linker2-Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL
重组融合多肽IV:Y-linker2-X;氨基酸序列为:
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL-linker2-PRCWRGEGGGGIVRRADRAAVPGGGGRGD。
上述重组融合多肽的linker1为:GGGGSGGGGSGGGGS;linker2为:AEAAAKEAAAKEAAAKEAAAKK。
优选的序列如下:
融合多肽1:
PRCWRGEGGGGIVRRADRAAVPGGGGRGDGGGGSGGGGSGGGGSSDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
融合多肽2:
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKLGGGGSGGGGSGGGGSPRCWRGEGGGGIVRRADRAAVPGGGGRGD;
融合多肽3:
PRCWRGEGGGGIVRRADRAAVPGGGGRGDAEAAAKEAAAKEAAAKEAAAKKSDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
融合多肽4:
Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKLAEAAAKEAAAKEAAAKEAAAKKPRCWRGEGGGGIVRRADRAAVPGGGGRGD;
本发明多肽还包括含有以上序列80%同源性的多肽序列。
1、克隆载体的构建
委托上海生工公司合成上述重组融合多肽的DNA序列,连接在商品化的表达载体上形成克隆载体,以上不同重组融合多肽克隆载体的构建过程一致。
2、重组融合多肽表达
瞬时转染是将DNA导入真核细胞的方式之一。在瞬时转染中,重组DNA导入感染性强的细胞系以获得目的基因暂时高水平的表达。可以在较短的时间内获得足够的目的蛋白样品用于实验研究,节约了稳定转染中所需的细胞筛选时间。使用商品化的Expi293Expression System或其他合适的瞬时转染表达系统,表达以上重组融合多肽,以上不同重组融合多肽表达过程相同,实验过程如下。
2.1质粒制备
从-80℃冰箱中取一支克隆载体保存菌株甘油管,接入含500mL Amp抗性LB培养基的2L摇瓶,37℃160rpm过夜震荡培养。培养结束后,5000g离心5min收集菌体,使用商业化的除内毒素质粒大提试剂盒提取质粒。将质粒浓度控制在1mg/mL以上,再用无菌0.22μm微孔滤膜过滤除菌,完成质粒制备。
2.2瞬时转染准备工作
用于转染的293F细胞或其他合适哺乳动物细胞,从复苏当天算起,每培养四天进行传代,至少进行三次传代再进行瞬时转染。传代过程中,根据最终转染培养基体积,按需扩大传代体积。
2.3瞬时转染(以30mL转染体积为例,根据需求成倍调整)
(1)实验前一天,将6*107的细胞接入30mL Expi293 Expression Medium,37℃,8%CO2,125rpm震荡培养。
(2)实验当天,先对前一天培养的细胞计数,细胞密度应为3-5*106cells/mL,活率大于95%。
(3)将7.5*107cells转入新的125mL锥形瓶,补加预热的Expi293 ExpressionMedium至25.5mL。
(4)准备质粒-转染试剂混合液
①将30μg质粒DNA复溶于1.5mL的Opti-MEM I Reduced Serum Medium,缓慢混匀。
②将81μL的ExpiFectamine 293Reagent加入Opti-MEM I Reduced SerumMedium,定容至1.5mL。轻轻混匀,室温孵育5min(长时间孵育将影响转化效率)。
③将上述两种溶液混合,轻轻混匀,室温孵育20-30min。完成质粒-转染试剂混合液准备工作。
(5)将3mL质粒-转染试剂混合液加入第(3)步的细胞培养液中。
(6)37℃,8%CO2,125rpm震荡培养20h。
(7)加入150μL的ExpiFectamine 293Transfection Enhancer 1和1.5mL的ExpiFectamine 293Transfection Enhancer 2。
(8)37℃,8%CO2,125rpm震荡培养。培养6天结束,收集细胞培养上清液进行目的蛋白纯化。
3、重组融合多肽纯化
采用合适的凝胶层析工艺进行纯化(如阳离子交换层析或/和阴离子交换层析等),收集纯化样品,以上重组融合多肽的纯化过程相同。
最后,采用10kDa超滤膜浓缩目的蛋白至浓度大于5mg/mL,然后分装样品(融合多肽1、2、3、4),于-80℃冰箱保存。采用SDS-PAGE和HPLC等方法对样品进行纯度检测,并用于体内外活性评价等成药性评价研究。
实施例2、肺纤维化动物模型实验动物及材料:
1.实验动物:
来源、种系、品系:清洁级SD大鼠,由扬州大学比较医学中心提供(实验动物生产许可证:SCXK(苏)2012-0004);实验动物使用许可证:SYXK(苏)2012-0035)。
体重:采购时体重180-200g,开始造模时体重190-210g,开始给药时为180-200g。
性别:雄性。
2.实验材料:
博来霉素 厂家:海正辉瑞药业。
生理盐水 厂家:安徽双鹤药业有限公司
水合氯醛 厂家:国药集团化学试剂有限公司
大鼠TGF-β1ELISA试剂盒 厂家:天津安诺瑞康生物科技有限公司
碱性HYP试剂盒 厂家:南京建成
BIBF1120(尼达尼布) 厂家:济南轩德化工有限公司;
3.实验方法:
SD大鼠,腹腔注射1mL/100g、4%的水合氯醛进行麻醉,大鼠麻醉后,固定大鼠,用75%酒精棉消毒大鼠颈部。用剪刀纵向剪开大鼠颈部皮肤,用镊子纵向钝性撕开筋膜与肌肉,暴露气管。注射器刺入气管注入博来霉素5mg/kg,空白组注入等量生理盐水。然后迅速将鼠板直立,旋转鼠板,观察大鼠呼吸情况,旋转后消毒颈部伤口,缝合伤口,并在缝合撒上阿莫西林消炎药。将术后大鼠放回干燥洁净的鼠笼休息,等待苏醒,大约l-2h后苏醒,之后正常饲养。造模后第7天造模组动物随机分为模型组、阳性药尼达尼布组、重组融合多肽1、2、3、4各个剂量组、正常对照组,并分别进行给药,给药周期为15天。每天观察老鼠的生存状况,称量其体重。给药15天之后,摘眼球取血,将其解剖,取肺。检测血清中TGF-β1的含量和肺组织中HYP的含量。
4.实验分组及剂量设置
表1实验分组及给药方案
注释:融合多肽1、2、3、4即为融合多肽I、II、III、IV,下同。
5.实验结果
(1)重组融合多肽对博来霉素诱导SD大鼠存活率的影响
如表2所示,较模型组SD大鼠存活率(50%)而言,各受试药的SD大鼠存活率均高于模型组,而且各受试药能够明显提高SD大鼠的存活率,融合多肽1、2、3的存活率均和阳性药组相当,而且融合多肽4的存活率(92.9%)高于阳性药组(85.7%)。
表2重组融合多肽对博来霉素诱导的SD大鼠肺纤维化的存活率(%)的影响
(2)重组融合多肽对博来霉素诱导的SD大鼠肺纤维化血清中TGF-β1含量的影响
取各组肺组织检测肺组织羟脯氨酸的含量,得到图1的结果,羟脯氨酸作为胶原蛋白的特征蛋白,可以侧面反映肺组织胶原的含量。TGF-β1是最为重要的致纤维化因子,在肺纤维化中,TGF-β1的表达含量明显增高,结果如图2所示,空白组和融合多肽2与模型组相比具有极其显著性差异(***P<0.001)给药之后,均可以显著降低血清中TGF-β1的含量,阳性药尼达尼布组、融合多肽1、3与模型组相比具有极其显著性的差异(**P<0.01),重组融合多肽4与模型组相比具有显著性的差异(*P<0.05)。
实施例3、肝纤维化动物模型
1.实验动物:
来源、种系、品系:SPF级SD大鼠,由上海西普尔-必凯实验动物有限公司提供(实验动物许可证:SCXK(沪)2013-0016)
体重:采购时体重180-200g,开始造模时体重200-220g
性别:雄性。
2.实验材料:
四氯化碳 厂家:上海Aladdin试剂公司
生理盐水 厂家:安徽双鹤药业有限公司
橄榄油 厂家:上海生工生物工程技术有限公司
碱性HYP试剂盒 厂家:南京建成
谷草转氨酶测试盒 厂家:南京建成
谷丙转氨酶测试盒 厂家:南京建成
3.实验方法
将雄性SD大鼠分为以下几组,分组见下面的表格,对其进行造模,除空白组外,其余各组一周两次,用40%的CCl4腹腔注射,首次以3mL/kg进行注射,随后以2mL/kg注射,造模8周,诱导成肝纤维化,自第4次腹腔注射CCl4后,按表3给药,诱导8周结束之后,停止给药,第二天对SD大鼠进行解剖,取血,取肝组织将其放在-80℃冰箱中保存备用。检测大鼠肝组织中HYP的表达含量。
4.实验分组及给药方案
表3实验分组及给药方案
5.实验结果
(1)各组大鼠肝组织中HYP的含量
取各组肝组织检测肝组织羟脯氨酸的含量,得到图3的结果,羟脯氨酸作为胶原蛋白的特征蛋白,可以侧面反映肝组织胶原的含量。如图3所示,模型组中HYP的含量明显高于空白组,重组融合多肽1、2、3、4和阳性药尼达尼布均可以显著的降低肝组织中HYP的表达,与模型组相比具有极其显著性的差异(***P<0.001)。
实施例4、肾纤维化动物模型
1.实验动物
清洁级雄性SD大鼠,购买自南京青龙山动物养殖场,采购时体重180-200g,开始造模时体重190-210g,开始给药时为180-200g。
2.实验材料:
生理盐水 厂家:安徽双鹤药业有限公司
大鼠TGF-β1ELISA试剂盒 厂家:天津安诺瑞康生物科技有限公司
碱性HYP试剂盒 厂家:南京建成
3.实验方法
肾纤维化动物模型的建立,SD大鼠用4%的水合氯醛进行麻醉,腹腔注射1mL/100g,将SD大鼠固定在手术板上,手术区域消毒备用,在腹中线偏左约3-4mm剪开腹腔,手术组分理处左肾输尿管,在靠近肾下极处结扎分离输尿管,然后双结扎后,在两个结扎中间剪短输尿管,卓曾缝合肌层及腹壁,酒精消毒,待SD大鼠苏醒后,放回笼内进行饲养。空白组不结扎输尿管,其余步骤相同。随后将动物分为空白组,模型组,重组融合多肽给药组,于手术后第二天开始给药,给药15天,给药15天之后,取血,取上清检测血清中TGF-β1的含量。
4.实验分组及剂量设置
表4实验分组及给药方案
5.实验结果
(1)重组融合多肽对肾纤维化SD大鼠血清中TGF-β1含量的影响
TGF-β1是最为重要的致纤维化因子,在肾纤维化中,TGF-β1的表达含量明显增高,结果如图4所示,模型组与空白组相比具有极显著性差异(***P<0.001)给药之后,各组均可以显著降低血清中TGF-β1的含量,重组融合多肽1、2、4与模型组相比均有极其显著性的差异(***P<0.001),重组融合多肽3与模型组相比具有极显著性的差异(**P<0.01)。
实施例5、心肌纤维化动物模型
1.实验小鼠:10周龄雄性BALB/c小鼠(体重平均20g)。
2.实验材料:
生理盐水 厂家:安徽双鹤药业有限公司
大鼠TGF-β1ELISA试剂盒 厂家:天津安诺瑞康生物科技有限公司
异丙肾上腺素(ISO) 厂家:Sigma
3.实验方法
模型组连续7天,每天给实验小鼠背部皮下注射异丙肾上腺素ISO(5mg/kg),同时每天采用生理盐水皮下注射(200μL/只)。空白组每天采用生理盐水皮下注射(200μL/只)。在造模的同时,给予重组融合多肽药物进行治疗,一天两次,皮下注射,第8天之后,取血,离心取上清,检测血清中的TGF-β1的含量4.实验分组及剂量设置
表5实验分组及给药方案
5.实验结果
(1)重组融合多肽对心肌纤维化小鼠血清中TGF-β1含量的影响
TGF-β1是最为重要的致纤维化因子,在心肌纤维化中,TGF-β1的表达含量明显增高,结果如图5所示,模型组与空白组相比具有极显著性差异(***P<0.001);给药之后,各组均可以显著降低血清中TGF-β1的含量,重组融合多肽2与模型组相比有极显著性的差异(***P<0.001),重组融合多肽1、3、4与模型组相比均具有显著性的差异(**P<0.01)。
实施例6、皮肤纤维化模型的建立
1.实验动物
6-8周龄的C57/BL雄性小黑鼠,后买自南京青龙山养殖场。
2.实验材料
博来霉素 厂家:海正辉瑞药业。
生理盐水 厂家:安徽双鹤药业有限公司
大鼠TGF-β1ELISA试剂盒 厂家:天津安诺瑞康生物科技有限公司
碱性HYP试剂盒 厂家:南京建成
3.造模方法
每天皮下注射博来霉素(10μg/mL),连续注射28天,使其形成皮肤纤维化,给药组在造模期间给药进行治疗。造模结束之后,第二天,小鼠处死,取其小鼠背部皮肤组织,检测皮肤组织中HYP的含量。
4.实验分组及给药方案
表6实验分组及给药方案
5.实验结果
(1)各组小鼠皮肤组织中HYP含量的表达
取小鼠背部皮肤组织检测皮肤组织中羟脯氨酸的含量,得到图6的结果,羟脯氨酸作为胶原蛋白的特征蛋白,可以侧面反映皮肤组织胶原的含量。如图6所示,重组融合多肽各组别均可以降低皮肤组织中HYP的表达;重组融合多肽2、4可以显著降低肺组织中HYP的表达,与模型组相比有极显著性差异(***P<0.001)。重组融合多肽1、3各组可降低SD大鼠肺组织中HYP的含量,与模型组相比有显著性差异(**P<0.01)。
实施例7、本发明的重组融合多肽对多种肺部感染的抑制作用
利用滴鼻法成功建立了小鼠肺炎模型,选择体质量为18-24g的BALB/C小鼠,分别在第0天、第1天和第2天用乙醚麻醉后,将制备好的肺炎链球菌菌液、腺病毒浓缩液、肺炎支原体、肺炎衣原体、原虫、肺炎真菌缓慢滴入小鼠的鼻腔,使其进入气管支气管后,在操作的过程中药防止菌液流入食道,导致菌液灭活,构建小鼠肺炎模型。待模型建立成功后,给予本发明的重组融合多肽,表7结果显示与青霉素给药组相比,本发明的重组融合多肽对多种肺部感染有更显著的改善作用,实验结果以平均值±标准差表示。如图7所示。
表7本发明的重组融合多肽对多种肺部感染的抑制效果
序列表
<110> 南京安吉生物科技有限公司
<120> 一种重组融合多肽及其应用
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 74
<212> PRT
<213> 多肽1(2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 1
Pro Arg Cys Trp Arg Gly Glu Gly Gly Gly Gly Ile Val Arg Arg Ala
1 5 10 15
Asp Arg Ala Ala Val Pro Gly Gly Gly Gly Arg Gly Asp Gly Gly Gly
20 25 30
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Asp Lys Pro
35 40 45
Gly Gly Gly Gly Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met Met
50 55 60
Gln Asn Gly Gly Gly Gly Leu Ser Lys Leu
65 70
<210> 2
<211> 74
<212> PRT
<213> 多肽2(2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 2
Ser Asp Lys Pro Gly Gly Gly Gly Thr Ser Leu Asp Ala Ser Ile Ile
1 5 10 15
Trp Ala Met Met Gln Asn Gly Gly Gly Gly Leu Ser Lys Leu Gly Gly
20 25 30
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Pro Arg Cys
35 40 45
Trp Arg Gly Glu Gly Gly Gly Gly Ile Val Arg Arg Ala Asp Arg Ala
50 55 60
Ala Val Pro Gly Gly Gly Gly Arg Gly Asp
65 70
<210> 3
<211> 81
<212> PRT
<213> 多肽3(2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 3
Pro Arg Cys Trp Arg Gly Glu Gly Gly Gly Gly Ile Val Arg Arg Ala
1 5 10 15
Asp Arg Ala Ala Val Pro Gly Gly Gly Gly Arg Gly Asp Ala Glu Ala
20 25 30
Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala
35 40 45
Ala Lys Lys Ser Asp Lys Pro Gly Gly Gly Gly Thr Ser Leu Asp Ala
50 55 60
Ser Ile Ile Trp Ala Met Met Gln Asn Gly Gly Gly Gly Leu Ser Lys
65 70 75 80
Leu
<210> 4
<211> 81
<212> PRT
<213> 多肽4(2 Ambystoma laterale x Ambystoma jeffersonianum)
<400> 4
Ser Asp Lys Pro Gly Gly Gly Gly Thr Ser Leu Asp Ala Ser Ile Ile
1 5 10 15
Trp Ala Met Met Gln Asn Gly Gly Gly Gly Leu Ser Lys Leu Ala Glu
20 25 30
Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Glu Ala
35 40 45
Ala Ala Lys Lys Pro Arg Cys Trp Arg Gly Glu Gly Gly Gly Gly Ile
50 55 60
Val Arg Arg Ala Asp Arg Ala Ala Val Pro Gly Gly Gly Gly Arg Gly
65 70 75 80
Asp
Claims (5)
1.一种重组融合多肽,其特征在于所述的融合多肽的氨基酸序列为如下任意一条:PRCWRGEGGGGIVRRADRAAVPGGGGRGDGGGGSGGGGSGGGGSSDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
SDKPGGGGTSLDASIIWAMMQNGGGGLSKLGGGGSGGGGSGGGGSPRCWRGEGGGGIVRRADRAAVPGGGGRGD;
PRCWRGEGGGGIVRRADRAAVPGGGGRGDAEAAAKEAAAKEAAAKEAAAKKSDKPGGGGTSLDASIIWAMMQNGGGGLSKL;
SDKPGGGGTSLDASIIWAMMQNGGGGLSKLAEAAAKEAAAKEAAAKEAAAKKPRCWRGEGGGGIVRRADRAAVPGGGGRGD。
2.根据权利要求1所述的一种重组融合多肽在制备抗纤维化药物中的应用;
所述的纤维化包括肺纤维化、肝纤维化、肾纤维化、心肌纤维化、皮肤纤维化。
3.根据权利要求1所述的一种重组融合多肽在制备抗肺组织病变药物中的应用;所述的抗肺组织病变包括细菌性肺炎、病毒性肺炎、支原体肺炎、真菌性肺炎、衣原体肺炎、原虫性肺炎。
4.根据权利要求2所述的一种重组融合多肽在制备抗纤维化药物中的应用,其特征在于,所述的抗纤维化药物为多肽或可接受的盐,剂型为由多肽或者盐制备的注射剂、胶囊、片剂、鼻喷剂或气雾剂。
5.根据权利要求3所述的一种重组融合多肽在制备抗肺组织病变药物中的应用,其特征在于,所述的抗肺组织病变药物为多肽或可接受的盐,剂型为由多肽或者盐制备的注射剂、胶囊、片剂、鼻喷剂或气雾剂。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910795102.XA CN110511285B (zh) | 2019-08-27 | 2019-08-27 | 一种重组融合多肽及其应用 |
PCT/CN2020/123551 WO2021037289A2 (zh) | 2019-08-27 | 2020-10-26 | 一种重组融合多肽及其应用 |
CA3149605A CA3149605A1 (en) | 2019-08-27 | 2020-10-26 | Recombinant fused polypeptide and use thereof |
US17/635,952 US20220289801A1 (en) | 2019-08-27 | 2020-10-26 | Recombinant fused polypeptide and use thereof |
AU2020339061A AU2020339061A1 (en) | 2019-08-27 | 2020-10-26 | Recombinant fusion polypeptide and use thereof |
GB2201004.5A GB2600845A (en) | 2019-08-27 | 2020-10-26 | Recombinant fusion polypeptide and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910795102.XA CN110511285B (zh) | 2019-08-27 | 2019-08-27 | 一种重组融合多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110511285A CN110511285A (zh) | 2019-11-29 |
CN110511285B true CN110511285B (zh) | 2023-01-24 |
Family
ID=68627164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910795102.XA Active CN110511285B (zh) | 2019-08-27 | 2019-08-27 | 一种重组融合多肽及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220289801A1 (zh) |
CN (1) | CN110511285B (zh) |
AU (1) | AU2020339061A1 (zh) |
CA (1) | CA3149605A1 (zh) |
GB (1) | GB2600845A (zh) |
WO (1) | WO2021037289A2 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110511285B (zh) * | 2019-08-27 | 2023-01-24 | 南京安吉生物科技有限公司 | 一种重组融合多肽及其应用 |
CN113069531B (zh) * | 2021-04-09 | 2023-02-28 | 南开大学 | 一种防疤痕皮肤创伤修复用水凝胶及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1328569A (zh) * | 1998-11-24 | 2001-12-26 | 纳瓦拉公司科学与技术研究所 | TGFβ1-抑制肽 |
CN105713095A (zh) * | 2016-03-14 | 2016-06-29 | 南京安吉生物科技有限公司 | 一种多功能融合多肽及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110511285B (zh) * | 2019-08-27 | 2023-01-24 | 南京安吉生物科技有限公司 | 一种重组融合多肽及其应用 |
-
2019
- 2019-08-27 CN CN201910795102.XA patent/CN110511285B/zh active Active
-
2020
- 2020-10-26 GB GB2201004.5A patent/GB2600845A/en active Pending
- 2020-10-26 AU AU2020339061A patent/AU2020339061A1/en active Pending
- 2020-10-26 US US17/635,952 patent/US20220289801A1/en active Pending
- 2020-10-26 CA CA3149605A patent/CA3149605A1/en active Pending
- 2020-10-26 WO PCT/CN2020/123551 patent/WO2021037289A2/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1328569A (zh) * | 1998-11-24 | 2001-12-26 | 纳瓦拉公司科学与技术研究所 | TGFβ1-抑制肽 |
CN105713095A (zh) * | 2016-03-14 | 2016-06-29 | 南京安吉生物科技有限公司 | 一种多功能融合多肽及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CA3149605A1 (en) | 2021-03-04 |
GB2600845A (en) | 2022-05-11 |
CN110511285A (zh) | 2019-11-29 |
AU2020339061A1 (en) | 2022-03-10 |
GB202201004D0 (en) | 2022-03-09 |
WO2021037289A3 (zh) | 2021-04-22 |
US20220289801A1 (en) | 2022-09-15 |
WO2021037289A2 (zh) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106860855B (zh) | 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用 | |
WO2019196420A1 (zh) | 一种多肽及其皮肤修复功能的应用 | |
CN110511285B (zh) | 一种重组融合多肽及其应用 | |
WO2021037292A2 (zh) | 一种多肽及其应用 | |
US20220332763A1 (en) | Fused polypeptide and use thereof | |
Yang et al. | The protective effect of rhBNP on postresuscitation myocardial dysfunction in a rat cardiac arrest model | |
CN110372800B (zh) | 具有多功能活性的融合多肽及其应用 | |
US20230295233A1 (en) | Polypeptide for repairing mucosal damage or skin wound and use thereof | |
CN111892660B (zh) | 一种构建长qt综合征动物模型的多肽 | |
WO2021024265A1 (en) | Methods of treating non-infectious inflammatory disorders | |
KR101588309B1 (ko) | 펩티드, 조성물 및 그의 용도 | |
CN100372572C (zh) | 携带人胸腺素β4基因的重组质粒 | |
CN116789751B (zh) | 预防和/或治疗纤维化疾病的多肽及其应用 | |
CN116115619B (zh) | 利培酮在治疗器官纤维化中的应用 | |
CN108948158B (zh) | 四连接素模拟肽tnp及其应用 | |
CN116003529A (zh) | 多肽及其在修复黏膜损伤或皮肤损伤上的应用 | |
CN117159689A (zh) | 主要尿蛋白促进创伤愈合和减轻炎症的应用 | |
TW202330573A (zh) | 一種多肽在製備用於預防或治療皮膚損傷疾病產品中之應用 | |
CN114099637A (zh) | Apelin在制备治疗矽肺的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |